{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T13:22:10Z","timestamp":1740144130984,"version":"3.37.3"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,24]],"date-time":"2022-12-24T00:00:00Z","timestamp":1671840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,24]],"date-time":"2022-12-24T00:00:00Z","timestamp":1671840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100014848","name":"Arnold Ventures","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014848","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Dostarlimab (Jemperli, GlaxoSmithKline) is an anti-programmed death receptor-1 monoclonal antibody (anti-PD-1)\u00a0recently tested in a non-randomized, phase II trial (NCT04165772) which included patients with mismatch repair-deficient, locally advanced rectal cancer. Among the first 12 patients treated with dostarlimab, 100% achieved a clinical complete response with no patients experiencing progression or recurrence to date.\u00a0Most impressive, none required chemotherapy, radiotherapy or surgery the prevailing standard of care. In this paper, we discuss the impressive results of this trial and how they relate to cancer policy, as well as propose a novel trial methodology to assess dostarlimab.<\/jats:p>","DOI":"10.1186\/s13063-022-06988-1","type":"journal-article","created":{"date-parts":[[2022,12,24]],"date-time":"2022-12-24T04:22:23Z","timestamp":1671855743000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A novel trial methodology to test interventions with very large effect sizes: the case of dostarlimab in mismatch repair-deficient, locally advanced rectal cancer"],"prefix":"10.1186","volume":"23","author":[{"given":"Kerrington","family":"Powell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timoth\u00e9e","family":"Olivier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinay","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,12,24]]},"reference":[{"key":"6988_CR1","doi-asserted-by":"publisher","unstructured":"Cercek A, Lumish M, Sinopoli J, et al. PD-1 blockade in mismatch repair-deficient, locally advanced rectal cancer. N Engl J Med. 2022. https:\/\/doi.org\/10.1056\/NEJMoa2201445.","DOI":"10.1056\/NEJMoa2201445"},{"issue":"8","key":"6988_CR2","doi-asserted-by":"publisher","first-page":"e13802","DOI":"10.1111\/eci.13802","volume":"52","author":"K Powell","year":"2022","unstructured":"Powell K, Prasad V. Multiplicity: when many analytic plans are applied or many redundant studies are run, false-positive results are ensured. Eur J Clin Investig. 2022;52(8):e13802. https:\/\/doi.org\/10.1111\/eci.13802.","journal-title":"Eur J Clin Investig"},{"issue":"5","key":"6988_CR3","doi-asserted-by":"publisher","first-page":"e13730","DOI":"10.1111\/eci.13730","volume":"52","author":"K Powell","year":"2022","unstructured":"Powell K, Prasad V. Where are randomized trials necessary: are smoking and parachutes good counterexamples? Eur J Clin Investig. 2022;52(5):e13730. https:\/\/doi.org\/10.1111\/eci.13730.","journal-title":"Eur J Clin Investig"},{"issue":"1","key":"6988_CR4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1136\/bjsm.21.1.13","volume":"21","author":"N Ellitsgaard","year":"1987","unstructured":"Ellitsgaard N. Parachuting injuries: a study of 110,000 sports jumps. Br J Sports Med. 1987;21(1):13\u20137. https:\/\/doi.org\/10.1136\/bjsm.21.1.13.","journal-title":"Br J Sports Med"},{"issue":"7429","key":"6988_CR5","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1136\/bmj.327.7429.1459","volume":"327","author":"GC Smith","year":"2003","unstructured":"Smith GC, Pell JP. Parachute use to prevent death and major trauma related to gravitational challenge: systematic review of randomised controlled trials. Bmj. 2003;327(7429):1459\u201361. https:\/\/doi.org\/10.1136\/bmj.327.7429.1459.","journal-title":"Bmj."},{"issue":"1","key":"6988_CR6","doi-asserted-by":"publisher","first-page":"E31","DOI":"10.9778\/cmajo.20170088","volume":"6","author":"MJ Hayes","year":"2018","unstructured":"Hayes MJ, Kaestner V, Mailankody S, Prasad V. Most medical practices are not parachutes: a citation analysis of practices felt by biomedical authors to be analogous to parachutes. CMAJ Open. 2018;6(1):E31\u2013e38. https:\/\/doi.org\/10.9778\/cmajo.20170088.","journal-title":"CMAJ Open"},{"issue":"16","key":"6988_CR7","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1001\/jama.2012.13444","volume":"308","author":"TV Pereira","year":"2012","unstructured":"Pereira TV, Horwitz RI, Ioannidis JP. Empirical evaluation of very large treatment effects of medical interventions. Jama. 2012;308(16):1676\u201384. https:\/\/doi.org\/10.1001\/jama.2012.13444.","journal-title":"Jama."},{"issue":"14","key":"6988_CR8","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1056\/nejm200104053441401","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344(14):1031\u20137. https:\/\/doi.org\/10.1056\/nejm200104053441401.","journal-title":"N Engl J Med"},{"issue":"10","key":"6988_CR9","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"A Hochhaus","year":"2017","unstructured":"Hochhaus A, Larson RA, Guilhot F, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376(10):917\u201327. https:\/\/doi.org\/10.1056\/NEJMoa1609324.","journal-title":"N Engl J Med"},{"issue":"24","key":"6988_CR10","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1200\/jco.2015.66.2866","volume":"34","author":"H Bower","year":"2016","unstructured":"Bower H, Bj\u00f6rkholm M, Dickman PW, H\u00f6glund M, Lambert PC, Andersson TM. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016;34(24):2851\u20137. https:\/\/doi.org\/10.1200\/jco.2015.66.2866.","journal-title":"J Clin Oncol"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06988-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-022-06988-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-022-06988-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,27]],"date-time":"2022-12-27T08:06:30Z","timestamp":1672128390000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-022-06988-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,24]]},"references-count":10,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["6988"],"URL":"https:\/\/doi.org\/10.1186\/s13063-022-06988-1","relation":{},"ISSN":["1745-6215"],"issn-type":[{"type":"electronic","value":"1745-6215"}],"subject":[],"published":{"date-parts":[[2022,12,24]]},"assertion":[{"value":"11 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"n\/a.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"n\/a.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Vinay Prasad discloses research funding from Arnold Ventures; royalties from Johns Hopkins Press, Medscape, and MedPage; consulting fees from UnitedHealthcare and OptumRx; and subscriber fees from Patreon, YouTube, and Substack. All other authors have no financial nor non-financial conflicts of interest to report.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1044"}}